Concurrent Chemoradiotherapy for Stage IIIB Cervical Cancer-Global Impact Through Power

Affiliations

¹ Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
² Department of Radiation Medicine and Applied Science, University of California, San Diego.
³ Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, Maryland.

Comment

Chika R Nwachukwu et al. JAMA Oncol. 2018.

. 2018 Apr 1;4(4):514-515.

doi: 10.1001/jamaoncol.2017.5078.

¹ Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
² Department of Radiation Medicine and Applied Science, University of California, San Diego.
³ Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, Maryland.

No abstract available

Comment on

Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.
Shrivastava S, Mahantshetty U, Engineer R, Chopra S, Hawaldar R, Hande V, Kerkar RA, Maheshwari A, Shylasree TS, Ghosh J, Bajpai J, Gurram L, Gulia S, Gupta S; Gynecologic Disease Management Group. Shrivastava S, et al. JAMA Oncol. 2018 Apr 1;4(4):506-513. doi: 10.1001/jamaoncol.2017.5179. JAMA Oncol. 2018. PMID: 29423520 Free PMC article. Clinical Trial.